The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSomero Regulatory News (SOM)

Share Price Information for Somero (SOM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 335.00
Bid: 330.00
Ask: 340.00
Change: -3.00 (-0.90%)
Spread: 10.00 (3.03%)
Open: 335.00
High: 332.00
Low: 332.00
Prev. Close: 335.00
SOM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

COVID-19 Update

30 Mar 2020 07:00

RNS Number : 9499H
Somero Enterprises Inc.
30 March 2020
 

30 March 2020

Somero Enterprises, Inc.

("Somero" or the "Company")

 

COVID-19 Update

Somero Enterprises, Inc. (the "Company") provides the following update regarding in respect of the COVID-19 pandemic.

Trading update

On 11 March 2020 we reported accelerated trading in the US due to improvement weather conditions led to a strong end to 2019 and a positive start to 2020. We also noted in our 2019 results statement, that while the outbreak of the COVID-19 pandemic led to a brief stoppage in activity in China, we had yet to see a direct impact of the COVID-19 pandemic on customer projects outside of China.

Since that update and the rapid movement of government guidance in that time across different regions, we have seen a dramatic increase in pressure on our non-China markets with lockdowns implemented in a rapidly increasing number of geographies including across portions of the US. This is impacting not only customer projects but also the manner in which we conduct our operations.

Given the evolving nature of the COVID-19 pandemic, it is too early at this stage to provide earnings guidance in relation to the remainder of the current financial year, although we do consider it likely there will be a material impact. We are therefore withdrawing guidance for the full year.

Response to COVID-19

 

Health and safety

Our priority remains the health and wellbeing of our customers, partners and employees and we are continuing to ensure that we have the appropriate measures and precautions in place for their safety.

 

We are closely monitoring the ongoing developments in relation to the COVID-19 pandemic and are taking appropriate actions to comply with governmental mandates.

 

Financial measures

As is prudent, we are taking actions to manage short-term cost control while ensuring the business remains on a sound footing in the long term. This includes reducing operational costs, limiting our capital expenditures and optimizing our cash flows.

Accordingly, in the circumstances, the Board has taken the prudent, precautionary decision to defer payment of the final 2019 ordinary dividend of 13.0 US cents per share and the supplemental dividend of 7.7 US cents per share that were declared with the Company's 2019 full year results and scheduled to be paid on 30 April 2020. These two dividends combined represent an US$ 11.7m payment to shareholders. In accordance with Delaware Law, the US state in which Somero is incorporated, the Company is deferring the record date and payment date for the dividends and not cancelling the dividends. Therefore, these two dividends will now be paid on or about February 5, 2021 to shareholders of record close of business on January 8, 2021.

January 8, 2021 is currently the latest record date permitted by the London Stock Exchange in accordance with its standard dividend procedures. The timing of the record date and payment date will be kept under review, and dependent on business conditions, the Board may decide to accelerate or further defer the dates. The Board currently intends to maintain its current dividend policy going forward, although any 2020 dividend will be paid as a final dividend only, with no interim dividend payment made later this year.

In addition, the Board is taking the prudent decision to cancel the US$ 1.0m share buyback program.

Financial update

The Company's financial position remains strong, with no debt, a substantial net cash position that currently exceeds US$ 24.0m, and substantial access to liquidity through the Company's US$ 10.0m line of credit.

Outlook

While the implications of the COVID-19 pandemic are difficult to determine, the Board is confident in the health of our business and the long-term growth opportunities in front of us. The Board's view is supported not only by the Company's strong financial position, but also the solid, albeit temporarily paused, non-residential construction activity pipeline that remains across our global markets, particularly in the US where customers have previously reported project backlogs that extend well into 2020, and by the progress we are making with our long-term new product initiatives.

The Board will provide the market with updated guidance on the Company's performance and expectations of future performance as and when appropriate.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For further information, please contact:

 

Somero Enterprises, Inc. www.somero.com

Jack Cooney, CEO +1 239 210 6500

John Yuncza, CFO

Howard Hohmann, EVP Sales

 

finnCap Ltd (NOMAD and Broker)

Matt Goode (Corporate Finance) +44 (0)20 7220 0500

Carl Holmes (Corporate Finance)

Kate Bannatyne (Corporate Finance)

Tim Redfern/Richard Chambers (ECMO)

 

Alma PR (Financial PR Advisor) somero@almapr.co.uk

Rebecca Sanders-Hewett +44(0) 20 3405 0205

Susie Hudson

Sam Modlin

David Ison

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTSEWEDWESSELD
Date   Source Headline
24th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
12th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
10th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
8th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
5th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
4th Apr 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
22nd Mar 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Mar 20246:06 pmRNSTransaction in Own Shares and Total Voting Rights
19th Mar 20243:07 pmRNSRestricted Stock Units& Director/PDMR Shareholding
5th Mar 20247:00 amRNSFinal Results
7th Feb 20247:00 amRNSNotice of Investor Presentation
31st Jan 20247:00 amRNSTrading Update
5th Jan 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
4th Jan 20247:00 amRNSTransaction in Own Shares and Total Voting Rights
13th Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
11th Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
15th Nov 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
14th Nov 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
26th Oct 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
19th Oct 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
6th Oct 20237:55 amRNSTransaction in Own Shares and Total Voting Rights
2nd Oct 20237:00 amRNSBoard Change
27th Sep 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Sep 20238:49 amRNSTransaction in Own Shares and Total Voting Rights
18th Sep 20237:00 amRNSDirector/PDMR Shareholding & Change of NOMAD name
13th Sep 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
31st Aug 20237:00 amRNSInterim Results
29th Aug 20237:00 amRNSBoard Change
8th Aug 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
2nd Aug 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
31st Jul 20237:00 amRNSNotice of Investor Presentation
24th Jul 20237:00 amRNSTrading Update
5th Jul 20234:52 pmRNSTransaction in Own Shares and Total Voting Rights
4th Jul 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Jun 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
20th Jun 20237:00 amRNSTrading Update
14th Jun 20233:46 pmRNSTransaction in Own Shares and Total Voting Rights
12th Jun 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
18th May 20233:10 pmRNSResult of AGM
17th May 20236:10 pmRNSTransaction in Own Shares and Total Voting Rights
17th May 20237:00 amRNSAGM Statement
12th May 20232:26 pmRNSTransaction in Own Shares and Total Voting Rights
4th May 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
28th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
27th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights
26th Apr 20236:15 pmRNSUpdate re: RSUs & Director/PDMR Shareholding
26th Apr 20237:00 amRNSTransaction in Own Shares and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.